ResearcherOslo University HospitalActive in the last 2 years

Tero A. Aittokallio

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0886-9769; OpenAlex author ID A5016681267. Sources: OpenAlex.

Their work

Papers: 4 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 9

Papers, trials and grants by year

2026: 4 papers

Papers 4

Standardized workflow enables reproducibility of drug synergism detection: Results from a multi-center in vitro ring test on complex drug combinations in pancr… Co-author DOI 10.1016/j.biopha.2026.119575 ↗
Prognostic biomarker discovery in pancreatic cancer through hybrid ensemble feature selection and multi-omics data. Last author DOI 10.1186/s13040-026-00546-0 ↗
Biomarker discovery and patient stratification in pancreatic cancer using incomplete multi-omics data. Co-author DOI 10.1371/journal.pcbi.1014735 ↗
NFATC2 in pancreatic cancer-associated fibroblasts predicts treatment response and facilitates ERBB-targeted therapies Co-author DOI 10.64898/2026.04.04.716465 ↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

A. Lopez · 2 shared papers, 2026 · strength 0.79
- Paper Biomarker discovery and patient stratification in pancreatic cancer using incomplete multi-omics data. DOI 10.1371/journal.pcbi.1014735 ↗
- Paper Prognostic biomarker discovery in pancreatic cancer through hybrid ensemble feature selection and multi-omics data. DOI 10.1186/s13040-026-00546-0 ↗
Alejandra Paja-García · 1 shared paper, 2026 · strength 0.43
- Paper Biomarker discovery and patient stratification in pancreatic cancer using incomplete multi-omics data. DOI 10.1371/journal.pcbi.1014735 ↗
John Zobolas · 1 shared paper, 2026 · strength 0.36
- Paper Prognostic biomarker discovery in pancreatic cancer through hybrid ensemble feature selection and multi-omics data. DOI 10.1186/s13040-026-00546-0 ↗
Biswajyoti Sahu · 1 shared paper, 2026 · strength 0.29
- Paper NFATC2 in pancreatic cancer-associated fibroblasts predicts treatment response and facilitates ERBB-targeted therapies DOI 10.64898/2026.04.04.716465 ↗
Jiahao Guo · 1 shared paper, 2026 · strength 0.29
- Paper NFATC2 in pancreatic cancer-associated fibroblasts predicts treatment response and facilitates ERBB-targeted therapies DOI 10.64898/2026.04.04.716465 ↗
Caroline Sophie Verbeke · 1 shared paper, 2026 · strength 0.29
- Paper NFATC2 in pancreatic cancer-associated fibroblasts predicts treatment response and facilitates ERBB-targeted therapies DOI 10.64898/2026.04.04.716465 ↗
Alfredo Budillon · 1 shared paper, 2026 · strength 0.26
- Paper Standardized workflow enables reproducibility of drug synergism detection: Results from a multi-center in vitro ring te… DOI 10.1016/j.biopha.2026.119575 ↗
Maria Serena Roca · 1 shared paper, 2026 · strength 0.26
- Paper Standardized workflow enables reproducibility of drug synergism detection: Results from a multi-center in vitro ring te… DOI 10.1016/j.biopha.2026.119575 ↗
Veronica Barile · 1 shared paper, 2026 · strength 0.26
- Paper Standardized workflow enables reproducibility of drug synergism detection: Results from a multi-center in vitro ring te… DOI 10.1016/j.biopha.2026.119575 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.